Fig. 3From: Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosisChanges in age-matched hematopoietic cellularity at different time points following ruxolitinib therapy. Values less than 1.0 indicate decreased cellularity, 1.0 reflects normal marrow cellularity, while values greater than 1.0 indicate increased cellularityBack to article page